Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
AffiliationCancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom; Department of Medical Oncology, University Hospital of South Manchester Foundation Trust, Manchester M23 9LT, United KingdomCancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, United KingdomCancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, United KingdomMedical Oncology Unit, 2nd Department of Medicine, Attikon University Hospital, Haidari, Athens, GreeceMedical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, ItalyDepartment of Medical Oncology, University of Athens School of Medicine, Athens, Greece.
MetadataShow full item record
AbstractDuring the last decade, thoracic oncology has witnessed an unprecedented outburst of knowledge regarding molecular biology of non small-cell lung cancer (NSCLC). The implementation of high-throughput sequencing analysis and genomic technologies has led to the identification of novel molecular events that characterize NSCLC transformation and may represent critical oncogenic drivers amenable to targeted therapy. Among these, the presence of activating mutations of the epidermal growth factor receptor (EGFR) gene and of chromosomic rearrangements in the anaplastic-lymphoma kinase (ALK) proto-oncogene, have been the first well characterized genetic alterations with corresponding targeted agents to enter the clinical arena. Nevertheless, in the recent years a number of other oncogenic drivers beyond EGFR and ALK inhibition have emerged as novel molecular targets with potential therapeutic implications, including mutations in the genes KRAS, BRAF, HER2, PI3KCA and DDR2, as well as ROS1 and RET rearrangements and MET, HER2 and FGFR1 gene amplifications. The aim of this review is to provide comprehensive information on the novel therapeutic targets identified by recent preclinical evidence and to discuss developments in molecular treatments targeting these oncogenic drivers or actionable mutations beyond EGFR and ALK in advanced NSCLC.
CitationBeyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. 2015: Cancer Treat Rev
JournalCancer Treatment Reviews
- Targeted therapy for NSCLC with driver mutations.
- Authors: Minuti G, D'Incecco A, Cappuzzo F
- Issue date: 2013 Oct
- Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
- Authors: Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F
- Issue date: 2014 May
- Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
- Authors: Gainor JF, Shaw AT
- Issue date: 2013
- The impact of genomic changes on treatment of lung cancer.
- Authors: Cardarella S, Johnson BE
- Issue date: 2013 Oct 1
- Targeting the MET gene for the treatment of non-small-cell lung cancer.
- Authors: Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M
- Issue date: 2014 Feb